• Explore /
  • Poster
  • / A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

Abstract Poster

Authors

Komal Jhaveri

Komal L. Jhaveri

Memorial Sloan Kettering Cancer Center, New York, NY

Komal L. Jhaveri , Rinath Jeselsohn , Elgene Lim , Erika P. Hamilton , Kan Yonemori , J. Thaddeus Beck , Peter A. Kaufman , Sarah Sammons , Manali A. Bhave , Cristina Saura , Emiliano Calvo , Tarek Meniawy , Timothy Larson , Cynthia X. Ma , Javier García-Corbacho Sr., Shanshan Cao , Shawn T. Estrem , Jennifer L. Milata , Bastien Nguyen , Muralidhar Beeram

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT04188548

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1021)

DOI

10.1200/JCO.2022.40.16_suppl.1021

Abstract #

1021

Poster Bd #

399

Abstract Disclosures

Similar Posters

First Author: Komal L. Jhaveri

First Author: Elgene Lim

First Author: Mario Campone

First Author: Rachel M. Layman